Keyword: Bellicum Pharmaceuticals
The FDA lifted a clinical hold it placed on Bellicum's lead cell therapy, BPX-501, in January.
Bellicum reported encouraging data for its BPX-501, but its U.S. program remains under a clinical hold.
Just a few days after the FDA placed a clinical hold on its lead cell therapy for cancer, Bellicum has named an ex-Genentech executive as its CMO.
Bellicum suffered the setback after the FDA learned of three cases of brain damage possibly related to adjunct T-cell therapy BPX-501.
Rick Fair has become the latest to leave a Big Pharma as he exits as head of oncology at Roche/Genentech to become the new CEO and president of Texas biotech Bellicum.